# ğŸ’Š Pharmaceutical Pricing Analysis â€“ Cost of Treatment Study

## ğŸ“Œ Overview
This project analyzes the price variation of 11 antihypertensive drugs across four major therapeutic classes using Microsoft Excel. It aims to evaluate cost disparities among different brands and understand their potential impact on patient affordability â€” a concept central to **Health Technology Assessment (HTA)** and **Cost of Treatment (COT)** analysis.

---

## ğŸ¯ Objectives
- Assess brand-wise cost variation in commonly used antihypertensive drugs.
- Calculate % price variation using Excel-based formulas.
- Create visual and tabular summaries for interpretation.
- Derive insights relevant to HTA and Market Access roles.

---

## ğŸ“Š Excel Output Snapshots

### ğŸ”¹ Cost Analysis Table

![Cost Analysis Table](https://github.com/xniraj/Cost-of-Treatment-Analysis-Antihypertensives/blob/main/Costanalysis.png)

---

### ğŸ”¹ Visualization of Price Variation

![Chart](https://github.com/xniraj/Cost-of-Treatment-Analysis-Antihypertensives/blob/main/Chart.png)

---

## ğŸ› ï¸ Tools & Functions Used
- Microsoft Excel  
- Formulas: `XLOOKUP`, `% variation`, rounding, and formatting  
- Data Cleaning and Basic Dashboard  
- Conditional Formatting

---

## ğŸ“ˆ Key Insights
- **Atenolol (2.5 mg)** had the highest price variation at **880%**.
- **Prazosin (2.5 mg)** showed the lowest at **32.98%**.
- Major cost discrepancies exist across brands for the same molecule/dose.
- These findings underline the importance of **cost-conscious prescribing** and **market price monitoring**.

---

## ğŸ“Œ Relevance
This project demonstrates practical skills in:
- Healthcare data analytics
- Cost-effectiveness analysis
- Real-world drug pricing assessment  
Making it highly relevant for roles like **Associate Analyst â€“ COT / HTA / Market Access**.
